← Back to Clinical Trials
Recruiting NCT07480265

NCT07480265 Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07480265
Status Recruiting
Phase
Sponsor Necmettin Erbakan University
Condition Hypertension (HTN)
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2025-06-02
Primary Completion 2027-12

Trial Parameters

Condition Hypertension (HTN)
Sponsor Necmettin Erbakan University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-06-02
Completion 2027-12
Interventions
Homocysteine Measurement and Echocardiography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This prospective single-center observational study aims to evaluate the relationship between elevated plasma homocysteine levels and early echocardiographic abnormalities in patients with newly diagnosed essential hypertension. Adult patients diagnosed with essential hypertension within the previous 6 months will undergo clinical assessment, ambulatory blood pressure monitoring, electrocardiography, laboratory testing, and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis when image quality is adequate. Participants will be classified according to plasma homocysteine level using, and patients with elevated and normal homocysteine levels will be compared with respect to diastolic dysfunction and left ventricular and left atrial global longitudinal strain parameters. Clinical, laboratory, and echocardiographic data will also be used to develop a machine-learning based model for prediction of H-type hypertension.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 years or older * Newly diagnosed essential hypertension within the previous 6 months * Ability and willingness to provide informed consent * Availability for clinical evaluation, laboratory testing, ambulatory blood pressure monitoring, electrocardiography, and transthoracic echocardiography Exclusion Criteria: * Resistant hypertension * Secondary hypertension * Acute coronary syndrome within the previous 6 months * Major surgery within the previous 6 months * Known heart failure * Pulmonary hypertension * Congenital heart disease * Atrial fibrillation or atrial flutter * Moderate or severe valvular heart disease * Chronic kidney disease * Anemia * Current folate, vitamin B12, or vitamin B6 supplementation or treatment * Inadequate echocardiographic image quality for strain analysis * Known systemic conditions that may significantly affect plasma homocysteine levels

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology